192 results
Page 5 of 10
8-K
EX-99.1
e6swp412
11 May 23
Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results
7:01am
8-K
EX-99.1
l6tb3bp4 5rko2w8yh9s
25 Apr 23
Results of Operations and Financial Condition
4:31pm
8-K
EX-99.1
gy9aeqy0
12 Apr 23
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
8:59am
8-K
EX-99.1
3f5a975
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
kklnijta
4 Oct 22
Other Events
7:06am
8-K
v2guq
25 Aug 22
Departure of Directors or Certain Officers
6:05am
8-K
owv05wcammq
18 Aug 22
Other Events
4:06pm
8-K
EX-99.1
72h6hr i77k
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
8-K
v7i78
2 Jun 22
Other Events
9:03am
8-K
EX-1.1
tu2onk4
20 May 22
Entry into a Material Definitive Agreement
4:05pm
424B5
sfrxvnfg fekixdqt
20 May 22
Prospectus supplement for primary offering
4:02pm
424B5
p1e8hodhmwnswo
6 May 22
Prospectus supplement for primary offering
7:15am
8-K
EX-10.1
my50 u1vx30pme
6 May 22
Entry into a Material Definitive Agreement
6:02am
FWP
s958xbqnex5rf4keebv
5 May 22
Free writing prospectus
4:06pm
8-K
EX-99.1
t43aw 6sd
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.1
dosqsujc
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
l6z8mhcj w02o16
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am